Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.530220
Title: Use of a direct, positive selection strategy to generate improved prodrug-activating enzymes for cancer gene therapy
Author: Baker, Shelley Louise
Awarding Body: University of Birmingham
Current Institution: University of Birmingham
Date of Award: 2011
Availability of Full Text:
Access through EThOS:
Access through Institution:
Abstract:
E. coli NfsB nitroreductase (NTR) is currently being studied in combination with the prodrug CB1954, as a gene directed enzyme prodrug therapy. NTR reduces CB1954 at either the 2- or 4-nitro groups to produce highly cytotoxic hydroxylamine derivatives, using either NADH or NADPH as cofactor. Initial clinical trials suggest activity, with reduction in PSA and apparent delayed progression in some patients. This thesis is concerned with engineering the NTR enzyme to improve the efficiency of CB1954 activation, since this would be expected to improve the potential clinical efficacy. Site directed mutagenesis has been used to generate four libraries of NTR mutants with three small libraries having a maximum diversity of 6.4 x101 – 8.2 x 103 and a large library of 6.3 x 106 possible nucleotide combinations. A direct positive selection strategy, which utilises bacteriophage lambda and the SOS response, was used to select NTR variants with increase sensitivity for CB1954 from each library. NTR mutants with greatest sensitivity were analysed by bacterial IC50 assays. Despite considerable work to generate and optimise the large library, only one NTR enzyme was improved over WT. However the best mutant (T41G N71S) came from a small library, with an IC50 of 8 µM. The most promising NTR enzyme variants were column purified and their kinetic parameters and activity determined. T41G N71S showed good activity for CB1954 (0.52 µM s-1), being the second best mutant to date behind T41L N71S (0.90 µM s-1). Adenoviral vectors were generated and their ability to sensitise SKOV3 cancer cells tested. T41G N71S was ~2-fold improved relative to WT NTR. Purified enzymes were also tested with SKOV3 cells, with T41G N71S being ~2.6-fold improved relative to WT NTR. My best enzyme should be considered when planning future clinical trials using prodrug activation gene therapy with NTR.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.530220  DOI: Not available
Keywords: Q Science (General)
Share: